HUTCHMED (China) Limited Total Assets
HUTCHMED (China) Limited total assets. Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) holds total assets worth €1.75 Billion EUR (≈ $2.05 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see HUTCHMED (China) Limited (H7T1) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of HUTCHMED (China) Limited (2016–2025)
Total assets of HUTCHMED (China) Limited from 2016 to 2025. This chart illustrates how HUTCHMED (China) Limited's total assets have evolved over time, based on quarterly financial data. See H7T1 stock price for real-time trading data and today's change.
HUTCHMED (China) Limited - Asset Composition Analysis
HUTCHMED (China) Limited Total Assets Breakdown (December 2025)
HUTCHMED (China) Limited total assets breakdown as of December 2025. HUTCHMED (China) Limited's total assets of €1.75 Billion consist of 89.4% current assets and 10.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.1% |
| Accounts Receivable | €126.75 Million | 7.2% |
| Inventory | €41.13 Million | 2.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €3.11 Million | 0.2% |
Asset Composition Trend (2016–2025)
This chart illustrates how HUTCHMED (China) Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore H7T1 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HUTCHMED (China) Limited's current assets represent 89.4% of total assets in 2025, an increase from 48.9% in 2016.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 23.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 7.2% of total assets.
HUTCHMED (China) Limited Competitors by Total Assets
Key competitors of HUTCHMED (China) Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
HUTCHMED (China) Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.96 | 2.83 | 3.35 |
| Quick Ratio | 4.83 | 2.70 | 3.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.25 Billion | €689.99 Million | €372.34 Million |
HUTCHMED (China) Limited - Advanced Valuation Insights
This section examines the relationship between HUTCHMED (China) Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 1.05 |
| Asset Growth Rate (YoY) | 37.6% |
| Total Assets | €1.75 Billion |
| Market Capitalization | $1.84 Billion USD |
Valuation Analysis
Above Book Valuation: The market values HUTCHMED (China) Limited's assets above their book value (1.05x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: HUTCHMED (China) Limited's assets grew by 37.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HUTCHMED (China) Limited (2016–2025)
The table below shows the annual total assets of HUTCHMED (China) Limited from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.75 Billion ≈ $2.05 Billion |
+37.58% |
| 2024-12-31 | €1.27 Billion ≈ $1.49 Billion |
-0.44% |
| 2023-12-31 | €1.28 Billion ≈ $1.50 Billion |
+24.32% |
| 2022-12-31 | €1.03 Billion ≈ $1.20 Billion |
-25.00% |
| 2021-12-31 | €1.37 Billion ≈ $1.60 Billion |
+89.56% |
| 2020-12-31 | €724.12 Million ≈ $846.57 Million |
+55.68% |
| 2019-12-31 | €465.12 Million ≈ $543.78 Million |
-12.59% |
| 2018-12-31 | €532.12 Million ≈ $622.10 Million |
-11.01% |
| 2017-12-31 | €597.93 Million ≈ $699.05 Million |
+74.61% |
| 2016-12-31 | €342.44 Million ≈ $400.34 Million |
-- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more